Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is a multisystemic inherited vascular dysplasia that leads to nosebleeds and visceral arteriovenous malformations (AVMs). Anti-angiogenic drugs thalidomide and bevacizumab have been increasingly used off-label with variable results. The HHT wor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Orphanet J Rare Dis
Glavni autori: Buscarini, Elisabetta, Botella, Luisa Maria, Geisthoff, Urban, Kjeldsen, Anette D., Mager, Hans Jurgen, Pagella, Fabio, Suppressa, Patrizia, Zarrabeitia, Roberto, Dupuis-Girod, Sophie, Shovlin, Claire L.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360670/
https://ncbi.nlm.nih.gov/pubmed/30717761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-018-0982-4
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items